Open AccessComparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies
Author(s) -
Ashutosh Wadhwa,
Sherry Yin,
Brandi Freeman,
Rebecca B. Hershow,
Marie E. Killerby,
Anna R Yousaf,
Sandra Lester,
Lisa Mills,
Sean Buono,
Mary Pomeroy,
Daniel Owusu,
Victoria Chu,
Jacqueline E. Tate,
Sanjib Bhattacharyya,
P. Hall,
Natalie J. Thornburg,
Hannah L Kirking
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0255208
Subject(s) - spike protein , covid-19 , virology , antibody , coronavirus , sars virus , betacoronavirus , immunoglobulin g , biology , medicine , immunology , infectious disease (medical specialty) , outbreak , pathology , disease
Serologic assays developed for SARS-CoV-2 detect different antibody subtypes and are based on different target antigens. Comparison of the performance of a SARS-CoV-2 Spike-Protein ELISA and the nucleocapsid-based Abbott Architect TM SARS-CoV-2 IgG assay indicated that the assays had high concordance, with rare paired discordant tests results.